A. Zubel

发表

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

E. Van Cutsem, J. Tabernero, L. Paz-Ares, 2014, Clinical Cancer Research.

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

C. Bokemeyer, F. D. De Braud, C. Stroh, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

C. Bokemeyer, I. Bondarenko, I. Çelik, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix.

A. Zubel, C. Flechtenmacher, L. Edler, 2009, Gynecologic oncology.

Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC).

J. Baselga, F. Rojo, J. Tabernero, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study

C. Bokemeyer, A. Zubel, J. Aparicio, 2007 .

Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial

W. Scheithauer, A. Zubel, J. Maurel, 2007 .

Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study

Y. Humblet, A. Zubel, A. Gramont, 2005 .

A. Zubel, P. Zhu, W. Jurczak, 2017, The Lancet. Haematology.

Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial.

E. Van Cutsem, G. Folprecht, P. Rougier, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial

C. Köhne, G. Folprecht, A. Zubel, 2009 .

3003 ORAL Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial

W. Scheithauer, H. Lenz, A. Zubel, 2007 .

Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)

P. Rougier, A. Zubel, M. Peeters, 2005 .

Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC).

W. Scheithauer, A. Zubel, J. Maurel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4± cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study

C. Bokemeyer, I. Çelik, A. Zubel, 2009 .

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

C. Berking, A. Hauschild, D. Schadendorf, 2019, Oncotarget.

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

E. Van Cutsem, F. Ciardiello, C. Köhne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

R. Greil, A. Schneeweiss, J. Baselga, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

J. Baselga, Y. Bang, R. Salgia, 2017, BMC Cancer.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

C. Berking, A. Hauschild, D. Schadendorf, 2013, The Lancet. Oncology.

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.

N. Magné, B. Chauffert, J. Bourhis, 2020, The Lancet. Oncology.

A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.

J. Tabernero, R. Kurzrock, A. Stathis, 2012 .

Transient MEK inhibitor-associated retinopathy in metastatic melanoma.

M. Urner, R. Dummer, A. Zubel, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

R. Finn, A. Zubel, L. Anderson, 2014, British Journal of Cancer.

Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.

F. Lordick, T. Seufferlein, A. Zubel, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial

A. Schneeweiss, J. Baselga, A. Zubel, 2010 .

LBA35OVERALL SURVIVAL AND BIOMARKER RESULTS FROM A PHASE 2 STUDY OF MEK1/2 INHIBITOR BINIMETINIB (MEK162) IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA

C. Berking, A. Hauschild, D. Schadendorf, 2014 .

Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations.

C. Berking, A. Hauschild, D. Schadendorf, 2012 .

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

W. Scheithauer, H. Lenz, A. Zubel, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of progesterone on simultaneous, local secretion of IGFBP-3 and IGF-I [IGFBP-3/IGF-I index] by human malignant and non-malignant breast explants depends on tissue steroid receptor phenotype.

A. Zubel, J. Stachura, T. Milewicz, 2003, Ginekologia polska.

Transient MEK inhibitor-associated retinopathy in metastatic melanoma.

M. Urner, R. Dummer, A. Zubel, 2014 .

3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS

C. Bokemeyer, A. Zubel, E. Starosławska, 2007 .

994OEquivalent efficacy of a biosimilar rituximab and reference rituximab in previously untreated advanced follicular lymphoma: Extended results of ASSIST-FL, a confirmatory phase III study

A. Zubel, P. Zhu, W. Jurczak, 2017 .

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

C. Bokemeyer, F. D. De Braud, C. Stroh, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC)

W. Scheithauer, A. Zubel, J. Maurel, 2005 .

Expression of ADAM9 in CIN3 lesions and squamous cell carcinomas of the cervix.

A. Zubel, C. Flechtenmacher, L. Edler, 2009, Gynecologic oncology.

J. Baselga, Y. Bang, R. Salgia, 2017, BMC Cancer.

Abstract 2437: MEK162 (ARRY 438162), a MEK1/2 inhibitor, has activity in melanoma cells independent of BRAF and NRAS mutation status.

Ke Gong, R. Finn, A. Zubel, 2013 .